XML 81 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Restructuring, Impairment, and Related Charges, Net - Summary of Activity Related to Restructuring Liability (Details) - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Cost Alignment Plan      
Beginning balance $ 55 $ 92  
Restructuring, impairment, and related charges, net 344 115 $ 209
Non-cash charges (98) (43)  
Cash payments (164) (105)  
Other (11) (4)  
Ending balance 126 55 92
Operating Segments | U.S. Pharmaceutical      
Cost Alignment Plan      
Beginning balance 18 15  
Restructuring, impairment, and related charges, net 59 17 38
Non-cash charges (58) (4)  
Cash payments (8) (15)  
Other (1) 5  
Ending balance 10 18 15
Operating Segments | Prescription Technology Solutions      
Cost Alignment Plan      
Beginning balance 5 26  
Restructuring, impairment, and related charges, net 12 11 43
Non-cash charges (9) 0  
Cash payments (4) (32)  
Other (3) 0  
Ending balance 1 5 26
Operating Segments | Medical-Surgical Solutions      
Cost Alignment Plan      
Beginning balance 1 3  
Restructuring, impairment, and related charges, net 204 11 10
Non-cash charges (14) 0  
Cash payments (99) (13)  
Other (2) 0  
Ending balance 90 1 3
Operating Segments | International      
Cost Alignment Plan      
Beginning balance 10 13  
Restructuring, impairment, and related charges, net 1 21 35
Non-cash charges (1) (10)  
Cash payments (2) (5)  
Other (7) (9)  
Ending balance 1 10 13
Corporate      
Cost Alignment Plan      
Beginning balance 21 35  
Restructuring, impairment, and related charges, net 68 55 83
Non-cash charges (16) (29)  
Cash payments (51) (40)  
Other 2 0  
Ending balance 24 21 35
Other Accrued Liabilities      
Cost Alignment Plan      
Beginning balance 24 66  
Ending balance 103 24 66
Other Noncurrent Liabilities      
Cost Alignment Plan      
Beginning balance 31 26  
Ending balance $ 23 $ 31 $ 26